Exelixis and Ipsen Announce Positive CHMP Opinion for Cabometyx in Previously Treated Hepatocellular Carcinoma

Exelixis and Ipsen Announce Positive CHMP Opinion for Cabometyx in Previously Treated Hepatocellular Carcinoma

Source: 
CP WIre
snippet: 
  • Exelixis is eligible to receive a milestone payment of $40 million for the approval of the second-line treatment of HCC
  • In May of 2018, the FDA accepted for filiing an sNDA for Cabometyx for previously treated advanced HCC
  • A Prescription Drug User Fee Act (PDUFA) action date of January 14 was assigned